What Will Be the Psychotropic Drugs of Tomorrow?

The development of psychotropic has slowed over the last two decades for essentially economic reasons; the drug industry has invested more in the field of oncology and autoimmune diseases. However, there are still avenues to explore, such as allostery for the development of drugs in the field of anxiety depression, bipolarity in particular. Other concepts are suggested in this article as the β-arrestins potential therapeutic targets in Alzheimer's disease (AD), the inhibitors of phosphodiesterase 10A for Huntington's disease, and the epigenetic in schizophrenia, peroxisome proliferator-activated receptors in neurodegenerative diseases.